First Trust Advisors’s BridgeBio Pharma BBIO Stock Holding History

First Trust Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.5M	Sell	247,738 -92,169	-27%	-$6.46M	0.01%	958
2026 Q1	$25.2M	Buy	339,907 +58,221	+21%	+$4.22M	0.02%	816
2025 Q4	$21.5M	Buy	281,686 +36,161	+15%	+$2.37M	0.02%	857
2025 Q3	$12.8M	Sell	245,525 -18,168	-7%	-$886K	0.01%	1029
2025 Q2	$11.4M	Buy	263,693 +175,918	+200%	+$6.4M	0.01%	1047
2025 Q1	$3.03M	Buy	+87,775	New	+$2.96M	﹤0.01%	1581
2024 Q2	–	Sell	-153,951	Closed	-$4.76M	–	2320
2024 Q1	$4.76M	Sell	153,951 -27,746	-15%	-$944K	﹤0.01%	1314
2023 Q4	$7.34M	Buy	181,697 +59,791	+49%	+$1.8M	0.01%	1106
2023 Q3	$3.21M	Sell	121,906 -69,595	-36%	-$1.97M	﹤0.01%	1472
2023 Q2	$3.29M	Buy	+191,501	New	+$2.88M	﹤0.01%	1449
2023 Q1	–	Sell	-152,241	Closed	-$1.16M	–	2360
2022 Q4	$1.16M	Buy	152,241 +36,203	+31%	+$347K	﹤0.01%	1913
2022 Q3	$1.15M	Buy	+116,038	New	+$1.21M	﹤0.01%	1937

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

First Trust Advisors's BBIO Position: Q2 2026 in Review

First Trust Advisors reduced its BridgeBio Pharma (BBIO) stake by 27% in Q2 2026, selling an estimated $6.46M and leaving 247,738 shares worth $18.5M. The position accounts for 0.01% of the portfolio, ranked #958.

First Trust Advisors first reported a position in BBIO in Q3 2022 and has held it in 12 quarters since. The position peaked at $25.2M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

First Trust Advisors held 247,738 shares of BridgeBio Pharma worth $18.5M as of Q2 2026.
First Trust Advisors sold 92,169 BridgeBio Pharma shares in Q2 2026, an estimated $6.46M.
BridgeBio Pharma made up 0.01% of First Trust Advisors's portfolio in Q2 2026, its #958 holding.
First Trust Advisors first reported a position in BridgeBio Pharma in Q3 2022 and has held it in 12 quarters since.
First Trust Advisors's BridgeBio Pharma position peaked at $25.2M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.